TLRY · Tilray Brands
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $3.21
Note written ·
Price against the kill line
24.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $3.21, on record since 11 November 2026. The shares are down 45.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $3.21, the highest close of the last 20 sessions (15 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 31 August 2026, filed 8 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 257
- Revenue, change on a year (%)
- +22.7
- Gross margin (%)
- 30.1
- Operating margin (%)
- −9.4
- Net cash, cash less debt ($M)
- 91.3
- Enterprise value to sales (×)
- 0.3
All filed numbers
What Tilray Brands reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 257 | +22.7 | 30.1 | −9.4 |
| first filed | 282 | +25.5 | 32.1 | −5.8 |
| first filed | 207 | +11.3 | 26.6 | −12.8 |
| first filed | 218 | +3.1 | 26.4 | −10.2 |
| first filed | 210 | +4.7 | 27.4 | 1.0 |
| first filed | 225 | −2.3 | 30.1 | −643.1 |
| Pre-tax income ($M) | −38.3 |
| Net income ($M) four quarters: −164 | −43.1 |
| Diluted shares, change on a year (%) against the quarter to 31 August 2025 | +25.8 |
| Operating cash flow ($M) | −84.3 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 218 |
| Debt ($M) non-current long-term debt plus short-term borrowings | 127 |
| Net cash, cash less debt ($M) | 91.3 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 191 |
| Inventory ($M) | 329 |
| Shareholders' equity ($M) | 1,623 |
| Market value ($M) | 359 |
| Enterprise value, market value plus net debt ($M) | 268 |
| Enterprise value to sales (×) | 0.3 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 0.2 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 14.6% of shares outstanding sold short, 4.5 days of average trading to cover, +14.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $69K | $233K |
The thesis
Tilray Brands has raised the low end of its fiscal 2027 adjusted EBITDA target and announced two cost-cutting programmes, yet the shares closed at $2.65 on 10 November 2026 and the target stays unproven until second-quarter results, expected around 8 January 2027. Adjusted EBITDA means earnings before interest, taxes, depreciation and amortization, with company adjustments.
Benzinga reported on 2 November 2026 that Tilray now targets $70–75 million, up from $68–75 million, after the company announced a consolidation of its Canadian cannabis operations. Tilray's own first-quarter release of 8 October 2026 had reaffirmed the old range, and first-quarter adjusted EBITDA was $9.2 million against $10.2 million a year earlier.
The shares are 81.0% below their 52-week high of $13.94 and fell 43.6% over three months, according to adjusted daily closes. The 14-day relative strength index (RSI), a gauge of recent selling pressure, is 40.8 on 10 November 2026. The index was 11.2 on 28 October 2026, so the extreme selling has eased.
The rescheduling narrative has faded as a price driver: the administrative law judge's 22 October 2026 order set reply briefs for 5 November 2026, and a recommended decision on Schedule III cannot arrive before the briefing closes. The live story is now cost savings and beverage growth, and it is new and unproven.
Bullish and bearish views on Tilray Brands, Inc.
The bull case on Tilray Brands, Inc. (TLRY), in brief: guidance floor moved up. The bear case: profit is far below the run-rate the target needs.
Bull case
- Guidance floor moved up. Benzinga reported on 2 November 2026 that the fiscal 2027 adjusted EBITDA target is now $70–75 million, against $68–75 million in the 8 October 2026 release. Fiscal 2026 adjusted EBITDA was $61.1 million.
- Two cost programmes are under way. On 29 October 2026 Tilray targeted about $20 million of annualized savings through fiscal 2028 by closing or selling several brewing and warehouse facilities in its U.S. beverage business. On 2 November 2026 it added about $10 million by fiscal 2028 from moving cultivation and pre-roll production from Fenwick, Ontario, to Masson, Quebec, and Cayuga, Ontario, per Benzinga.
- Revenue and margin grew. Net revenue rose 23% to $257.1 million in the quarter ended 31 August 2026, and gross margin rose to 30% from 27%, per the company's 8 October 2026 release.
- Cash covers near-term debt. Cash, restricted cash and marketable securities were $221.4 million at 31 August 2026, against $59.2 million of convertible debentures classed as current.
- Selling pressure has eased. The RSI recovered from 11.2 on 28 October 2026 to 40.8 on 10 November 2026, and Benzinga reported the shares up about 2% to $2.58 on 2 November 2026.
Bear case
- Profit is far below the run-rate the target needs. First-quarter adjusted EBITDA was $9.2 million, against a full-year target whose low end is $70 million. Management says results skew to the second half, so the January report is the first real test.
- Savings arrive over years. Both cost programmes are stated through the end of fiscal 2028, which ends 31 May 2028, so most of the benefit falls outside fiscal 2027.
- Core cannabis is shrinking. Cannabis revenue was $56.1 million against $64.5 million a year earlier, per the 8 October 2026 release. Beverage grew 82% to $101.5 million, which the company ties largely to the BrewDog acquisition.
- Revenue missed and the loss was large. Benzinga reported sales of $257.1 million against an analyst estimate of $267.8 million on 8 October 2026. Net loss was $40.0 million, or $0.32 per share.
- Dilution continues. Shares outstanding were 144.9 million at 31 August 2026, up from 131.7 million at 31 May 2026, as 5.20% convertible notes due 15 June 2027 are exchanged for shares.
- Targets are coming down. Canaccord Genuity kept Hold and cut its target to $4 on 9 October 2026, per Benzinga.
Price setup
The last close was $2.65 on 10 November 2026, per adjusted daily closes. That is slightly below the $2.69 close of 28 October 2026. The 52-week high is $13.94.
A rebound has not yet returned the shares above $2.90.
Crowding evidence is mixed. Benzinga Pro data cited on 2 November 2026 show short interest of 21.5 million shares, or 14.8% of the public float, so a short-covering rise is possible. Share issuance through note exchanges continues into weakness, and each exchange is disclosed only after it closes. No earnings report falls inside the next 30 days.
The narrative around the cost programmes is accelerating only in the sense of fresh news: two announcements in five days, with no analyst reaction found in the first week.
Catalysts ahead
- ~8 January 2027 (est.): Second-quarter fiscal 2027 results. Tests management's claim that adjusted EBITDA skews to the second half and whether the $70–75 million target holds.
Elapsed catalysts
- ~12 November 2026 (est.): Hemp-derived THC recriminalization takes effect under the Continuing Appropriations Act. A deferral or enforcement change would be a sector-wide signal; Tilray said in November 2025 it expected no material revenue impact. (passed)
What would change the view
A daily close above $3.21, the highest close of the last 20 sessions (15 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Tilray trades with US and Canadian cannabis shares on rescheduling headlines, though beverage is its largest segment, which dilutes sensitivity to US cannabis policy. The shares also react to its own convertible-note dilution, which is independent of the sector.
The evidence, claim by claim (7)
- Tilray raised the low end of its fiscal 2027 adjusted EBITDA outlook to $70–75 million from $68–75 million and plans about $10 million of annualized savings by end of fiscal 2028 from consolidating Canadian cannabis production. Benzinga, 2 November 2026 · as of
- Tilray targeted about $20 million of annualized cost savings through fiscal 2028 in U.S. beverage and planned to dispose of several brewing and warehouse facilities. Tilray announcement headlines, 29 October 2026 · as of
- First-quarter fiscal 2027 net revenue was $257.1 million, up 23%; adjusted EBITDA $9.2 million vs $10.2 million a year earlier; net loss $40.0 million. Tilray Q1 fiscal 2027 press release (Form 8-K exhibit 99.1) · as of
- Cannabis revenue was $56.1 million vs $64.5 million a year earlier; beverage $101.5 million, up 82%. Tilray Q1 fiscal 2027 press release (Form 8-K exhibit 99.1) · as of
- Cash, restricted cash and marketable securities were $221.4 million; shares outstanding 144.9 million vs 131.7 million at 31 May 2026. Tilray Q1 fiscal 2027 press release (Form 8-K exhibit 99.1) · as of
- Short interest was 21.5 million shares, 14.8% of the public float. Benzinga Pro data cited by Benzinga, 2 November 2026 · as of
- Canaccord Genuity kept Hold on Tilray and lowered its price target to $4. Benzinga headline, 9 October 2026 · as of
Sources
Related · shared themes